SG11202102110PA - Novel hydrochloride salt forms of a sulfonamide structured kinase inhibitor - Google Patents
Novel hydrochloride salt forms of a sulfonamide structured kinase inhibitorInfo
- Publication number
- SG11202102110PA SG11202102110PA SG11202102110PA SG11202102110PA SG11202102110PA SG 11202102110P A SG11202102110P A SG 11202102110PA SG 11202102110P A SG11202102110P A SG 11202102110PA SG 11202102110P A SG11202102110P A SG 11202102110PA SG 11202102110P A SG11202102110P A SG 11202102110PA
- Authority
- SG
- Singapore
- Prior art keywords
- sulfonamide
- structured
- kinase inhibitor
- hydrochloride salt
- salt forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/04—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20185743 | 2018-09-06 | ||
| PCT/FI2019/050629 WO2020049217A1 (fr) | 2018-09-06 | 2019-09-05 | Nouvelles formes salines de chlorhydrate d'un inhibiteur de kinase à structure sulfamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202102110PA true SG11202102110PA (en) | 2021-04-29 |
Family
ID=67982092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202102110PA SG11202102110PA (en) | 2018-09-06 | 2019-09-05 | Novel hydrochloride salt forms of a sulfonamide structured kinase inhibitor |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11866420B2 (fr) |
| EP (1) | EP3846906A1 (fr) |
| JP (1) | JP7528060B2 (fr) |
| KR (1) | KR20210057759A (fr) |
| CN (1) | CN112805065B (fr) |
| AU (1) | AU2019334693A1 (fr) |
| CA (1) | CA3111040A1 (fr) |
| EA (1) | EA202190696A1 (fr) |
| MA (1) | MA53546A (fr) |
| MX (1) | MX2021002524A (fr) |
| SG (1) | SG11202102110PA (fr) |
| WO (1) | WO2020049217A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023516358A (ja) * | 2020-03-05 | 2023-04-19 | オーリジーン ディスカバリー テクノロジーズ リミテッド | キナーゼ阻害剤の医薬組成物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111382C2 (uk) | 2011-10-10 | 2016-04-25 | Оріон Корпорейшн | Інгібітори протеїнкінази |
| US10870637B2 (en) * | 2017-03-23 | 2020-12-22 | Orion Corporation | Process for the preparation of a sulfonamide structured kinase inhibitor |
| WO2020135878A1 (fr) * | 2018-12-29 | 2020-07-02 | 南京明德新药研发有限公司 | Dérivé d'imidazopyridine utilisé en tant qu'inhibiteur double de fgfr et vegfr |
| AU2020292664B2 (en) * | 2019-06-14 | 2023-04-13 | Cgenetech (Suzhou, China) Co., Ltd. | Fused ring compound as FGFR and VEGFR dual inhibitor |
-
2019
- 2019-09-05 CA CA3111040A patent/CA3111040A1/fr active Pending
- 2019-09-05 AU AU2019334693A patent/AU2019334693A1/en active Pending
- 2019-09-05 KR KR1020217010097A patent/KR20210057759A/ko active Search and Examination
- 2019-09-05 CN CN201980058119.5A patent/CN112805065B/zh active Active
- 2019-09-05 MX MX2021002524A patent/MX2021002524A/es unknown
- 2019-09-05 SG SG11202102110PA patent/SG11202102110PA/en unknown
- 2019-09-05 WO PCT/FI2019/050629 patent/WO2020049217A1/fr unknown
- 2019-09-05 JP JP2021512769A patent/JP7528060B2/ja active Active
- 2019-09-05 EP EP19769549.7A patent/EP3846906A1/fr active Pending
- 2019-09-05 EA EA202190696A patent/EA202190696A1/ru unknown
- 2019-09-05 US US17/273,774 patent/US11866420B2/en active Active
- 2019-09-05 MA MA053546A patent/MA53546A/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN112805065B (zh) | 2024-07-05 |
| CN112805065A (zh) | 2021-05-14 |
| MA53546A (fr) | 2021-12-15 |
| CA3111040A1 (fr) | 2020-03-12 |
| JP7528060B2 (ja) | 2024-08-05 |
| MX2021002524A (es) | 2021-04-28 |
| US11866420B2 (en) | 2024-01-09 |
| WO2020049217A1 (fr) | 2020-03-12 |
| JP2022501328A (ja) | 2022-01-06 |
| KR20210057759A (ko) | 2021-05-21 |
| EA202190696A1 (ru) | 2021-06-16 |
| EP3846906A1 (fr) | 2021-07-14 |
| US20210332028A1 (en) | 2021-10-28 |
| AU2019334693A1 (en) | 2021-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FIC20240021I1 (fi) | Adagrasibi tai sen farmaseuttisesti hyväksyttävä suola | |
| MA42606A (fr) | Sels d'un inhibiteur de lsd1 | |
| IL263739B (en) | History of n-(converted-phenyl)-sulfonamide as kinase inhibitors | |
| IL283860A (en) | Crystalline forms and salt forms of a kinase inhibitor | |
| IL288484A (en) | Crystalline salt forms of a kinase inhibitor | |
| MA42780A (fr) | Sels d'un inhibiteur de la kinase pim | |
| MA54901A (fr) | Inhibiteur de 15-pgdh | |
| EP3825309A4 (fr) | Sel d'inhibiteur de lsd1 et polymorphe de celui-ci | |
| IL287630A (en) | Solid forms of glyt1 inhibitor | |
| DK3749646T3 (da) | Heteroaryl-forbindelser som kinase-inhibitor | |
| IL267393A (en) | Crystal forms of a Janus kinase inhibitor | |
| DK3286190T3 (da) | Farmaceutiske saltformer af en inhibitor af semicarbazid-sensitiv aminoxidase (ssao) | |
| ZA202103581B (en) | Novel aminophosphinic derivatives as aminopeptidase a inhibitors | |
| SG11202102110PA (en) | Novel hydrochloride salt forms of a sulfonamide structured kinase inhibitor | |
| IL281599A (en) | TYK2 kinase inhibitors | |
| IL274027A (en) | B-RAF kinase inhibitor salt crystals | |
| GB201907193D0 (en) | Obtaining patterns for surfaces of objects | |
| IL277578A (en) | New salt forms of URAT-1 inhibitors | |
| IL279953A (en) | Crystal forms of LTA4H inhibitor | |
| GB201919212D0 (en) | Dihydro-cyclopenta-isoquinoline sulfonamides derivatives | |
| GB201807845D0 (en) | Kinase Inhibitors | |
| TWI852963B (zh) | 激酶抑制劑之結晶形式及鹽形式 | |
| FIC20190048I1 (fi) | Lorlatinibi tai sen farmaseuttisesti hyväksyttävä suola | |
| FIC20190033I1 (fi) | Apalutamidi tai sen farmaseuttisesti hyväksyttävä suola | |
| GB201517197D0 (en) | A casein Kinase 1 delta inhibitor |